The Guardian World· World
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmakerBusiness live – latest updatesBritain’s biggest drugmaker, AstraZeneca, is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.AstraZeneca, run by Pascal Soriot, its longtime chief executive, i
Published Monday, 3 August 2026 at 07:58
Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmakerBusiness live – latest updatesBritain’s biggest drugmaker, AstraZeneca, is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second-biggest listed company in the UK, with a market value of nearly £196bn before the news broke. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn. Continue reading...
This is a syndicated summary. Read the full story at the original publisher:
Read on The Guardian World →